RxDoctor Payments Data

Evelyn Lewis, MD

Nephrology · Atlanta, GANPI 1730274218

Payments from drug & device makers

$3,577in general payments, 2019–2025

Across 108 payments — averaging $33.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pacira Pharmaceuticals Incorporated$862
  • AstraZeneca$659
  • Amgen$317
  • Fresenius USA Marketing, Inc.$256
  • Ardelyx, Inc.$155
  • Boehringer Ingelheim$134
  • plus $1K from 15 others

What the payments were for

  • Travel & lodging$86224%
  • Food & beverage$2,57372%
  • Education$1424%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,577 in reported general payments places this provider in the 65th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$137,163
Medicare patients
213
Services billed
1,075

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide18$58,204
FarxigaDapagliflozin Propanediol41$41,025
JardianceEmpagliflozin62$38,760
KerendiaFinerenone25$15,937
Sevelamer Carbonate62$9,107
LokelmaSodium Zirconium Cyclosilicate23$9,036
ProsolParenteral Amino Acid 20% No.148$8,402
Nifedipine ErNifedipine70$2,085
Torsemide98$2,075
Losartan Potassium122$892
Hydralazine Hcl65$880
Midodrine Hcl11$865
Valsartan28$825
Calcium Acetate19$575
Carvedilol87$557

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$256$58,20418 claims
AstraZenecaFarxiga, Lokelma$659$50,06264 claims
Boehringer IngelheimJardiance$134$38,76062 claims
BayerKerendia$48$15,93725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 388 nephrology providers in Georgia.

Other nephrology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →